Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you should play QTTB shares heading into 2026.
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease...
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand;Â topline data readout expected in mid-2026 --
-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients --
WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia...
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 --